C5 and hereditary angioedema: Two complement drugs, C1 esterase inhibitor (C1-INH) and the anti-C5 antibody drug eculizumab/Soliris, have reached market, although C1-INH is FDA-approved for an indication not primarily mediated by complement (hereditary angioedema (HAE)).